echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Sansheng Guojian HER2/PD-1 bispecific antibody was approved by the U.S. FDA...

    Sansheng Guojian HER2/PD-1 bispecific antibody was approved by the U.S. FDA...

    • Last Update: 2021-06-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On June 14th, Sansheng Guojian announced that a clinical trial evaluating the bispecific antibody SSGJ-705 has recently been approved by the U.


    SSGJ-705 is a recombinant anti-HER2 x anti-PD-1 bispecific antibody injection (abbreviated as "BsAb")


    SSGJ-705 related preclinical research results have been published in the core journal Acta Pharmacologica Sinica recently


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.